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Background: Vaccination Week in the Americas (VWA) is an annual initiative in countries and territories of the
Americas every April to highlight the work of national expanded programs on immunization (EPI) and increase
access to vaccination services for high-risk population groups. In 2011, as part of VWA, Venezuela targeted children
aged less than 6 years in 25 priority border municipalities using social mobilization to increase institution-based
vaccination. Implementation of social communication activities was decentralized to the local level. We conducted
a survey in one border municipality of Venezuela to evaluate the outcome of VWA 2011 and provide a snapshot of
the overall performance of the routine EPI at that level.
Methods: We conducted a coverage survey, using stratified cluster sampling, in the Venezuelan municipality of Bolivar
(bordering Colombia) in August 2011. We collected information for children aged <6 years through caregiver interviews
and transcription of vaccination card data. We estimated each child’s eligibility to receive a specific vaccine dose during
VWA 2011 and whether or not they were actually vaccinated during VWA activities. We also estimated baseline
vaccination coverage, timeliness and 95% confidence intervals (CI), and used chi-square tests to compare coverage across
age cohorts, taking into account the sampling design.
Results: We surveyed 839 children from 698 households; 93% of children had a vaccination card. Among households
surveyed, 216 (31%) caregivers reported having heard about a vaccination activity during April or May 2011. Of the 528
children eligible to receive a vaccine during VWA, 24% received at least one dose, while 13% received all doses due.
Overall, baseline coverage with routine vaccines, as measured by the survey, was >85%, with a few exceptions.
Conclusion: Low levels of VWA awareness among caregivers probably contributed to the limited vaccination of eligible
children during the VWA activities in Bolivar in 2011. However, vaccine coverage for most EPI vaccines was high.
Additionally, high vaccination card availability and high participation in VWA among those caregivers aware of it in 2011
suggest public trust in the EPI program in the municipality. Health authorities have used survey findings to inform
changes to the routine EPI and better VWA implementation in subsequent years.
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The Bolivarian Republic of Venezuela's Expanded Program
on Immunization (EPI) strives to protect its citizens against
vaccine-preventable diseases (VPDs); however, suboptimal
performance has left multiple birth cohorts susceptible to
VPDs. Over the past 3 decades, Venezuela has achieved
<85% reported coverage with third dose of diphtheria-
tetanus-pertussis [DTP3] vaccine, the common indicator
for immunization program performance [1]. Groups at
risk for suboptimal immunization coverage include indi-
genous populations, those in border, urban and hard-to-
reach zones, displaced populations and those in areas
where population growth exceeds the capacity of health
services.
Vaccination Week in the Americas (VWA) is an annual
initiative carried out by countries and territories in the Re-
gion of the Americas and supported by the Pan American
Health Organization/World Health Organization (PAHO/
WHO) [2,3]. VWA began in 2003 based on a proposal
by ministers of health of six countriesa in response to a
large measles outbreak in Venezuela and Colombia in
2002 [4]; the proposal called for a coordinated annual
international vaccination effort. The initiative’s objectives
include highlighting the work of national immunization
programs and increasing access to vaccination services,Table 1 Routine vaccination schedule in Venezuela, 2011
Vaccine Recommended age(s)
BCG1 Birth
Hepatitis B (1st dose) Birth
Yellow fever 1 year
OPV2
- Primary series 2 m, 4 m, 6 m
- Booster 18 m, 5 years
Pentavalent3
- Primary series 2 m, 4 m, 6 m
- Pentavalent4 (1st DTP Booster) 18 m
Rotavirus 2 m, 4 m
DTP4
- 2nd DTP booster 5 years
MMR5 1 year, 5 years
Td6 10 years, women of childbe
Influenza (annual) 6-23 months
>60 years
High-risk groups
23-valent pneumococcal >60 years
m=months.
1BCG = Bacillus Calmette-Guérin.
2OPV = oral poliovirus vaccine.
3Pentavalent = diphtheria and tetanus toxoids, and pertussis, Haemophilus influenzae
4DTP = diphtheria and tetanus toxoids and pertussis vaccine.
5MMR =measles-mumps-rubella vaccine.
6Td = Tetanus and diphtheria toxoids for older children and adults.particularly for hard-to-reach, high-risk groups. Specific
campaigns undertaken as part of VWA are flexible and
chosen by countries based on their public health priorities
[5]. VWA’s success has inspired establishment of similar
initiatives in other regions, leading to the 2012 launch of
World Immunization Week, endorsed by the World
Health Assembly [6].
In Venezuela, VWA is a comprehensive initiative encom-
passing multiple activities including advocacy with political
and technical authorities, social communication and
mobilization and increased availability of vaccination ser-
vices. These activities are intended to help position EPI on
the political agenda, increase visibility of the program, and
improve coverage [7]. The VWA 2011 campaign in
Venezuela included targeting children aged less than 6 years
of age who were eligible for one or more vaccine doses in
the national schedule (Table 1), with emphasis on those
who lived in one of 25 high risk border municipalities, se-
lected based on reported low coverage the year prior. The
main strategy was increased social mobilization for
institution-based vaccinations. Across the region, VWA
2011 was officially scheduled from April 23rd to April 30th,
but in Venezuela it extended through the month of May.
Bolivar is one of 29 municipalities in the western An-
dean state of Táchira and was one of the prioritizedYear of introduction
1940s
2000
2000
1960s
2009
2004
2006 (modified 2009)
2009
MMR 1 (1998); MMR 2 (2009)
aring age, adults 2009 (replaced TT, used since the 1950s)
2006
2008
type b and hepatitis B vaccines.
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la’s border with the Republic of Colombia and experi-
ences constant population movement due to commercial
activities between the two countries; in 2011, the popu-
lation of Bolivar was 74,568 individuals [8]. Because
the municipality contains urban, periurban, and rural
areas, as well as displaced populations, the Venezuelan
Ministry of Health (MOH) selected Bolivar as the site
for an evaluation of VWA 2011, including a post-VWA
immunization coverage survey [9]. This coverage sur-
vey was supported by PAHO and the United States
Centers for Disease Control and Prevention (CDC)
and represents one of the few methodologically rigor-
ous evaluations performed over the 12 years of VWA.
Methods
Target area and population
Our coverage survey was conducted on August 13–14,
2011. For MOH and PAHO, it was considered an oper-
ational study and not research. The protocol was
reviewed by the human subjects coordinator for CDC’s
Center for Global Health, and was considered a pro-
grammatic evaluation and exempt from institutional
board review of human subjects research. The survey’s
target area included the municipality of Bolivar, subdi-
vided into the areas of San Antonio del Táchira (the
municipality’s capital and predominately urban area),
Palotal (periurban area) and a rural area consisting of
Juan Vicente Gómez and Isaías Medina Angarita par-
ishes. Children were eligible to participate if they were
less than 6 years of age during April and May 2011.
Survey design
We calculated a sample size of 267 children eligible to
be vaccinated during VWA 2011 assuming 50% of eli-
gible children would receive at least one vaccine, preci-
sion of ±6%, and probability of achieving precision of
0.95. We used binomial distribution to calculate a sam-
ple size of 720 children less than 6 years of age, based
on the assumption only 40% of target age children
would be eligible for at least one vaccine and to ensure
90% probability of identifying the target of 267 eligible
children.
We used a stratified 30-cluster survey design, propor-
tionally allocating clusters to the 3 areas based on popu-
lation size (22 in San Antonio del Táchira, 5 in Palotal,
and 3 in the rural area). In each stratum, we selected
clusters (barrios) with replacement and probability of se-
lection proportional to size. We used population esti-
mates from MOH and included 24 households with at
least one child less than 6 years old in each cluster. We
selected an area within the cluster using a 10x10 grid
superimposed over a map of the cluster and chose one
cell within the grid via simple random sampling. Thefirst house within that cell was also chosen at random
and from there, we visited all subsequent households to
the right, until 24 households with at least one child less
than 6 years of age had been surveyed.
Data collection
A total of 44 interviewers were trained who were health
workersb from Bolivar. Survey teams consisted of two in-
terviewers and one supervisor who accompanied two or
three teams. Survey teams were assigned to areas outside
of their normal jurisdiction and collected data on all
children in the target age range within a participating
household.
Survey teams administered a standardized question-
naire to any available caregiver (e.g. mother, father,
grandmother, etc.), to collect information about the
caregiver’s education, household demographics, type of
health center routinely visited, awareness about a vaccin-
ation activity conducted in their community during
April or May 2011, and, when applicable, the caregiver’s
actions in response to that knowledge. Survey teams
transcribed information in each child’s vaccination card
(doses received and dates of administration). When a
card was not available, teams reviewed the health center’s
vaccination records; teams did not collect caregivers’ rec-
ollections about specific vaccine doses received, but did
record responses to questions about the campaign and
communication. We trained data entry staff who entered
data into an EpiInfo® (CDC, Atlanta, GA, USA) database.
In the field, accuracy of data entry was reviewed by the
technical focal point from the national immunization
program.
Data analysis
We used SAS v9.2 (SAS Institute, Inc., Cary, NC, USA),
SUDAAN® v10 (RTI International, Research Triangle
Park, NC, USA), and R v3.0 (R Foundation for Statistical
Computing, Vienna, Austria) to clean and analyze data.
We restricted vaccination-related analyses to children
with information available through vaccination cards
(and for a small minority, health center records). We de-
termined each child’s eligibility to receive a specific vac-
cine dose during VWA 2011 based on their date of birth
and the information recorded regarding specific doses
received. We calculated proportions of children who re-
ceived any vaccine doses, specific vaccine doses, or all
vaccine doses for which they were eligible during VWA
2011 (April 23, 2011 – May 31, 2011). We used all vac-
cine doses transcribed, regardless of when they were ad-
ministered, to estimate overall coverage of specific
vaccines at the time of the survey, by five 1-year age co-
horts. We estimated vaccination coverage, 95% confi-
dence intervals (CI), and Chi-square tests to compare
coverage across age cohorts, taking into account the
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stratum-level weights (estimated target population in
each stratum divided by sample size in each stratum) in
SUDAAN. We used R survey package [10] to estimate
time to vaccination and 95% CIs (Aalen [hazard-based]
estimator) for each dose of pentavalent vaccinec (Penta)
and first dose of measles-mumps-rubella vaccine
(MMR1). The results are presented in graphs as 1 minus
time to vaccination to show estimated change in prob-
ability of being vaccinated through 24 months of age
(Penta) and 36 months of age (MMR1). To show uncer-
tainty around the estimated curve, 95% CIs for probabil-
ity of vaccination are calculated and plotted at each time
point that an event (i.e., child is vaccinated) occurs.
Results
Households surveyed
We surveyed caregivers of 839 children less than six
years of age in 698 households, including 513 (74%)
households in the urban area of San Antonio del
Táchira, 114 (16%) in the semi-urban Palotal, and 71
(10%) in the rural area. Most (84%) were mothers; 8% were
grandmothers. Fifty-nine percent of caregivers reported
having completed high school or university education.
Fifty-two percent of eligible children were female.
Among caregivers surveyed, 90% reported using public
outpatient and hospital settings for routine vaccination
services, while 5% utilized private institutions and 5% re-
ported other institutions. Among 698 households sur-
veyed, 216 (31%, 95% CI 25-38%) respondents reported
having heard about a vaccination activity during April or
May 2011. Among these 216, 152 (70%, 95% CI 59-81%)
reported having heard about a general campaign, while
only 20 (9%, 95% CI 5-18%) identified VWA 2011 specif-
ically. The most common sources of information among
those aware of a recent vaccination activity were radio
(28%, 95% CI 17-39%) and the local health center (20%,
95% CI 13-29%). When caregivers were asked how they
responded after learning about a vaccination activity,
63% (95% CI 54-73%) reported bringing their child to
the health center with a vaccination card, 7% (95% CI 2-
19%) said they brought their child without a vaccination
card, 25% (95% CI 17-34%) indicated that they did not
bring their child to the vaccination site and 5% (95% CI
2-10%) of responses were classified as “other”.
Vaccination during VWA 2011 and EPI coverage
Among 839 surveyed children, 784 (93%) had a vaccin-
ation card, and for an additional 6 (1%) children, vaccin-
ation data were available from clinic records. Among all
790 children with available vaccination data, 528 (67%,
95% CI 63-71%) were age-eligible to receive at least one
vaccine dose during VWA 2011 (Table 2). Among these,
126 (24%) received at least one dose for which they wereeligible, and 69 (13%) received all indicated doses.
Among the 126 children who received at least one vac-
cination, 57 (45%) did not receive all vaccinations for
which they were eligible. Among 18 children eligible to
receive Bacillus Calmette-Guérin vaccine (BCG) and 13
eligible for the first dose of hepatitis B, 16 (89%) and 11
(85%) received BCG and hepatitis B, respectively, repre-
senting the largest proportion of eligible children to re-
ceive an indicated vaccine dose. By contrast, among
children eligible to receive yellow fever vaccine (N = 127),
the second booster dose of oral polio vaccine (OPV2)
(N = 45), or the second MMR dose (MMR2) (N = 87),
only 3 (2%), 1 (2%), and 4 (5%), respectively, received
the recommended vaccine(s).
Vaccination coverage
BCG coverage estimates were at least 95% for each 1-year
age cohort; however, coverage with birth dose of hepatitis
B vaccine was lower, with the lowest being 81% (95% CI
71-88%) in children aged 24–35 months (Table 3).
Coverage with Penta3 exceeded 90% in most cohorts,
and was generally higher than coverage with OPV3,
which ranged from 86% in 12–23 month-olds to 96% in
48–59 month-olds. MMR1 coverage was only 72% (95%
CI 63-80%) among children aged 12–23 months, al-
though in older cohorts it was approximately 90%. Simi-
larly, yellow fever vaccine coverage estimates were
higher (92-95%) in older age cohorts but significantly
lower in younger age cohorts, with coverage estimates of
62% (95% CI 54-70%) among children aged 12–23
months and 82% (95% CI 75-87%) in children aged 24–
35 months. In contrast, second dose rotavirus vaccine
coverage estimates were highest in the two youngest age
cohorts (51% [95% CI 41-62%] among 12–23 month-olds
and 52% [95% CI 43–60] among 24–35 month-olds), but
were significantly lower in the three older age cohorts:
among children aged 60–71 months, coverage was only
21% (95% CI 14-29%). Coverage with first DTP and OPV
booster doses generally increased with increasing age,
from 59% (95% CI 52-66%) (DTP) and 64% (95% CI 55-
72%) (OPV) among children aged 24–35 months to 74%
(95% CI 62-83%) (DTP) and 81% (95% CI 69-90%) (OPV)
among children aged 48–59 months. First booster cover-
age for children aged 60–71 months continued to increase
for DTP at 77% (95% CI 67-85%) but fell slightly for OPV
to 79% (95% CI 66-88%). There were statistically signifi-
cant differences in coverage between birth cohorts for the
following vaccine doses: hepatitis B birth dose, Penta3,
MMR1, yellow fever vaccine, second rotavirus dose, and
first booster doses of DTP and OPV vaccines.
Timeliness of vaccination
Approximately 90% of children received the first dose of
pentavalent vaccine (Penta1) between 2 and 4 months of
Table 2 Age range of eligibility for receiving vaccine and proportion of eligible children vaccinated during Vaccination
Week of Americas, Bolivar, Venezuela, 2011
Vaccine Age eligibility (months) Minimum interval (after preceding dose),
if applicable
No. eligible No. (% of eligible)
vaccinated [95% CI]
BCG ≤12 18 16 (89)
Hepatitis B ≤1 13 11 (85)
Pentavalent1* ≥2 40 14 (35)
Pentavalent2* ≥4 ≥28 days (Penta1) 42 10 (24)
Pentavalent3* ≥6 ≥28 days (Penta2) 60 14 (23)
OPV1 ≥2 46 23 (50)
OPV2 ≥4 ≥28 days (OPV1) 52 18 (35)
OPV3 ≥6 ≥28 days (OPV2) 74 15 (20)
MMR1 ≥12 121 16 (13)
Yellow fever ≥12 127 3 (2)
Rotavirus1 2 - 4 20 8 (40)
Rotavirus2 4-8 ≥28 days (Rotavirus1) 11 6 (55)
Pentavalent4* (DTP boost1) ≥18 155 14 (9)
DTP boost2 ≥60 9 5 (56)
OPV boost1 ≥18 138 17 (12)
OPV boost2 ≥60 45 1 (2)
MMR2 ≥60 87 4 (5)
Any dose ≤72 528 126 (24) [20–28]
All indicated doses ≤72 528 69 (13) [10-16]
*Pentavalent = Diphtheria-Tetanus-Pertussis (DTP) + Haemophilus influenzae type b + Hepatitis B vaccines.
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decreased, even though coverage remained high. For ex-
ample, most cohorts only achieved 50-70% coverage
with Penta3 by the end of the recommended time of 6
to 8 months of age, although coverage by 8 months of
age was only about 40% in the 36–47 month group. By
24 months of age, all 5 cohorts had reached 80-95%
coverage with Penta3.
There was more variability between cohorts in MMR1
coverage and timeliness of vaccination (Figure 2). The
CI for the 12–23 month olds indicates coverage at
15 months was between 45 and 63%. The curves for the
23–35, 36–47, and 48–59 month groups indicate higher
coverage by 15 months. MMR1 coverage gradually in-
creased for all cohorts over the following two years.
Discussion
Although one of VWA’s objectives in Bolivar in 2011
was to improve immunization coverage, only an esti-
mated 24% of eligible children received at least one indi-
cated vaccine dose and only 13% received all doses due.
Overall, there was low awareness of VWA 2011; less
than one-third of caregivers heard about recent vaccin-
ation activities, which may have limited the initiative’s
reach. Nevertheless, vaccine coverage for most vaccines
at the time of the survey was above 85%.The proportion of children who benefitted from VWA
2011 was likely lower than our estimates indicate. Be-
cause VWA 2011 in Bolivar focused on increasing vac-
cination services in institutional settings that already
provided them, we were unable to distinguish between
vaccine doses provided because of VWA and those ad-
ministered irrespective of VWA. In addition, the largest
proportion of eligible children vaccinated were those
who received BCG or birth dose of hepatitis B vaccine.
However, these doses are typically administered follow-
ing hospital births and 95% of births in Bolivar are esti-
mated to occur in hospitals [11].
Although coverage with most vaccines was relatively
high among all cohorts, MMR1 coverage among 12–23
month-olds was lower at 72% (95% CI 63-80%) than
among older cohorts (88-93%). Analysis of timeliness
demonstrated that older cohorts also had lower levels of
coverage during the second year of life; however, con-
tinuing to offer immunization services to older children
resulted in higher coverage during succeeding months
and years, similar to findings reported elsewhere [12].
While the scope of this study did not address specific
reasons for the receipt of late doses, particularly for
Penta2 and Penta3, speculative reasons may include
population movement across the border to Colombia for
extended periods of time for employment, delaying the
Table 3 Vaccination coverage ascertained by vaccination card or medical records among 641 surveyed children aged 12–71 months (weighted), by birth
cohort, Bolivar, Venezuela, 2011
Vaccine dose
(recommended age)
12-23 months (n = 129) 24 – 35 months (n = 131) 36 - 47 months (n = 141) 48 – 59 months (n = 139) 60 - 71 months (n = 101)
No (%) [95% CI] who
received dose
No (%) [95% CI] who received dose No (%) [95% CI] who received dose No (%) [95% CI] who
received dose
No (%) [95% CI] who
received dose
BCG (birth) 123 (95) [89–98] 126 (96) [91–98] 139 (99) [94- > 99] 136 (98) [93–99] 99 (98) [93–99]
Hepatitis B* (birth) 112 (87) [81–91] 106 (81) [71–88] 131 (93) [86–97] 127 (92) [83–96] 86 (85) [77–91]
Penta3* (6 months) 117 (91) [85–94] 121 (92) [86–96] 127 (90) [83–94] 137 (99) [94- >99] 93 (92) [85–96]
OPV3 (6 months) 111 (86) [78–91] 121 (92) [86–96] 126 (89) [82–94] 133 (96) [91–98] 93 (92) [81–97]
MMR1* (12 months) 94 (72) [63–80] 116 (89) [81–94] 128 (91) [79–96] 129 (93) [85–97] 89 (88) [77–94]
Yellow fever* (12 months) 81 (62) [54–70] 107 (82) [75–87] 130 (92) [86–96] 132 (95) [88–98] 94 (93) [87–97]
Rotavirus2* (4–8 months) 67 (51) [41–62] 68 (52) [43–60] 53 (38) [28–48] 38 (27) [19–36] 21 (21) [14–29]
DTP booster1* (18 months) N/A N/A N/A 33 (59) [52–66] 87 (61) [48–73] 103 (74) [62–83] 78 (77) [67–85]
OPV booster1* (18 months) N/A N/A N/A 84 (64) [55–72] 91 (64) [57–75] 113 (81) [69–90] 80 (79) [66–88]
DTP booster2 (5 years) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 17 (17) [10–27]
OPV booster2 (5 years) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 34 (34) [22–47]
MMR2 (5 years) N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 27 (27) [18–37]
*p value <0.05 indicates a difference in coverage between birth cohorts for given vaccine dose.
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Figure 1 Time to vaccination, estimated as 1 – time to vaccination, and 95% point-wise CIs for all three doses of pentavalent vaccination among
children in 5 age groups, Bolivar, Venezuela, 2011. Gray shaded area indicates the timeliness window for each dose (PENTA1: 2–4 months, PENTA2:
4–6 months, PENTA3: 6–8 months).
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Venezuela, work obligations which limit the ability of
parents to bring their children to the health centers dur-
ing regular hours and the reduced use of house-to-house
vaccination strategies. Such concerns were part of the
reason that border municipalities were prioritized during
VWA 2011 in Venezuela, as the initiative represents one
strategy to identify those children with incomplete
schedules and improve coverage.
Social mobilization to raise population awareness of
public health interventions is essential [13-16], especially
for institution-based efforts that require population
turnout at health centers, as opposed to strategies such
as house-to-house vaccination. Implementation of the
VWA 2011 communication campaign was decentralized
to the local level and had limited oversight from the na-
tional EPI. In the future, efforts to ensure messages
about VWA reach a wide audience should use commu-
nication channels identified by caregivers in thisevaluation, such as radio and health centers. While ac-
cess to vaccination services was beyond the scope of this
survey, it merits further examination, especially in a
border municipality such as Bolivar which has high
population mobility.
High prevalence of vaccination cards in households,
high participation rate among caregivers aware of vac-
cination activities, and widespread use of public facilities
for vaccination services indicate public support of EPI in
Bolivar. Among children vaccinated, 45% did not receive
all indicated vaccines. This may be due to multiple rea-
sons, including those related to health care workers who
may have been uncomfortable administering multiple
vaccines, had misconceptions about contraindications,
or were hesitant to open new vaccine vials for fear of
wastage. There may have also been unknown vaccine
and supply shortages and it is possible that parents may
have been uncomfortable with their child receiving mul-
tiple vaccinations on the same day, among many other
Figure 2 Time to vaccination, estimated as 1 – time to vaccination, for MMR1 vaccination among children in 5 age groups, Bolivar, Venezuela, 2011.
Dotted lines represent 95% CI. Gray shaded area indicates the timeliness window (12–15 months) for the first dose of MMR.
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portunities in the future, additional health worker train-
ing and assessments of parental satisfaction regarding
their experience with the EPI should be considered.
Coverage for Penta3 in Bolivar was higher than the na-
tional coverage of 78% reported by Venezuela through
the WHO/UNICEF Joint Reporting Form for 2011 [18].
Lower coverage for yellow fever vaccine, especially
among children aged 12–23 months (63%) is likely due
to global vaccine shortages, causing stock-outs. Rota-
virus vaccine was introduced in Venezuela in 2006; be-
cause of this and the upper age limits for administering
vaccine, older children would have aged-out of eligibility
to receive the vaccine post-introduction, resulting in
lower coverage in these cohorts. The schedule for rota-
virus vaccination was modified in 2009, an operational
change that could have also affected coverage. Other re-
cent EPI schedule changes include the introduction of
MMR2 and second OPV and DTP boosters during
2009–2010. These changes may explain the lower cover-
age for these doses as health workers adapted to new
guidelines.
While our results exposed positive and negative as-
pects of implementation of VWA 2011 and the overall
EPI in Bolivar, Venezuelan health authorities have used
lessons learned for planning of subsequent vaccination
activities. For example, efforts to improve VWA social
communication and mobilization intensified in Bolivar
in 2012, 2013 and 2014, including new strategies such as
using loudspeakers. To optimize performance of routine
EPI, local health authorities have subdivided parishes of
the municipality and reassigned health workers to better
reach the population. Health authorities have alsocoordinated with community councils to conduct house-
to-house vaccination in specific difficult-to-reach and
low coverage areas. An additional vaccination post was
also opened in a hospital in Bolivar with extended even-
ing hours to increase opportunities for working parents
to have their children vaccinated.
The survey in Bolivar had several limitations. The sur-
vey was completed by multiple teams during an inten-
sive two-day effort over a weekend when most parents
are home. This decision was made to complete the sur-
vey quickly in order to maximize the efficiency of the
data collection process. The use of multiple teams may
have increased the risk of bias, but efforts were in place
to train and closely supervise the interviewers. The sur-
vey design was based on a quota sample of households
with at least one eligible child and not probability sam-
pling. As a result, we could not calculate the selection
probability of households or account for non-response.
To accurately determine VWA 2011 eligibility, we re-
stricted analysis to children with available vaccination
records. This may have led to overestimation of cover-
age; however, because card availability was high overall
within each age group, this bias was likely minimal.
Conclusion
Our evaluation provided important information regard-
ing the implementation and outcome of VWA 2011 in
one border municipality, and provided insight into the
performance of EPI in this challenging and dynamic
area. Because of the targeted nature of the survey, find-
ings cannot be generalized to VWA 2011 results in other
areas of the country, nor do they assess all components
of Venezuela’s multi-faceted VWA 2011 campaign. As
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World Immunization Week, similar surveys, adapted to
local realities, can help objectively assess execution and
outcomes of similar initiatives aimed at improving cover-
age and updating childhood vaccination schedules, while
providing lessons to adjust strategies and optimize re-
sults. Such surveys also serve as windows into routine
EPI implementation at the local level, and are thus im-
portant management tools. Constructive activities fol-
lowing survey results, such as Venezuela’s response since
2011, will help ensure that populations are protected
against VPDs and that disease eradication, elimination
and control goals are achieved and maintained.Endnotes
aBolivia, Chile, Colombia, Ecuador, Peru, and Venezuela
bIncluded nurses, “simplified medicine” assistants, and
social workers;
cPentavalent vaccine contains diphtheria toxoid, tet-
anus toxoids, pertussis vaccine, Haemophilus influenzae
type b (Hib) vaccine, and hepatitis B vaccine.
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